Your browser doesn't support javascript.
loading
Down-regulation of A20 promotes immune escape of lung adenocarcinomas.
Breitenecker, Kristina; Homolya, Monika; Luca, Andreea C; Lang, Veronika; Trenk, Christoph; Petroczi, Georg; Mohrherr, Julian; Horvath, Jaqueline; Moritsch, Stefan; Haas, Lisa; Kurnaeva, Margarita; Eferl, Robert; Stoiber, Dagmar; Moriggl, Richard; Bilban, Martin; Obenauf, Anna C; Ferran, Christiane; Dome, Balazs; Laszlo, Viktoria; Gyorffy, Balázs; Dezso, Katalin; Moldvay, Judit; Casanova, Emilio; Moll, Herwig P.
Affiliation
  • Breitenecker K; Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
  • Homolya M; Institute of Cancer Research, Medical University of Vienna, AT-1090 Vienna, Austria.
  • Luca AC; Comprehensive Cancer Center (CCC), Medical University of Vienna, AT-1090 Vienna, Austria.
  • Lang V; Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
  • Trenk C; Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
  • Petroczi G; Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
  • Mohrherr J; Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
  • Horvath J; Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
  • Moritsch S; Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
  • Haas L; Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
  • Kurnaeva M; Institute of Cancer Research, Medical University of Vienna, AT-1090 Vienna, Austria.
  • Eferl R; Comprehensive Cancer Center (CCC), Medical University of Vienna, AT-1090 Vienna, Austria.
  • Stoiber D; Research Institute of Molecular Pathology, Vienna Biocenter, AT-1030 Vienna, Austria.
  • Moriggl R; Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
  • Bilban M; Institute of Cancer Research, Medical University of Vienna, AT-1090 Vienna, Austria.
  • Obenauf AC; Comprehensive Cancer Center (CCC), Medical University of Vienna, AT-1090 Vienna, Austria.
  • Ferran C; Institute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, AT-1090 Vienna, Austria.
  • Dome B; Division Pharmacology, Department of Pharmacology, Physiology and Microbiology, Karl Landsteiner University of Health Sciences, AT-3500 Krems, Austria.
  • Laszlo V; Institute of Animal Breeding and Genetics, University of Veterinary Medicine, AT-1210 Vienna, Austria.
  • Gyorffy B; Department of Laboratory Medicine, Medical University of Vienna, AT-1090 Vienna, Austria.
  • Dezso K; Core Facilities, Medical University of Vienna, AT-1090 Vienna, Austria.
  • Moldvay J; Research Institute of Molecular Pathology, Vienna Biocenter, AT-1030 Vienna, Austria.
  • Casanova E; Division of Vascular and Endovascular Surgery and the Center for Vascular Biology Research, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  • Moll HP; Transplant Institute and the Division of Nephrology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Sci Transl Med ; 13(601)2021 07 07.
Article in En | MEDLINE | ID: mdl-34233950
ABSTRACT
Inflammation is a well-known driver of lung tumorigenesis. One strategy by which tumor cells escape tight homeostatic control is by decreasing the expression of the potent anti-inflammatory protein tumor necrosis factor alpha-induced protein 3 (TNFAIP3), also known as A20. We observed that tumor cell intrinsic loss of A20 markedly enhanced lung tumorigenesis and was associated with reduced CD8+ T cell-mediated immune surveillance in patients with lung cancer and in mouse models. In mice, we observed that this effect was completely dependent on increased cellular sensitivity to interferon-γ (IFN-γ) signaling by aberrant activation of TANK-binding kinase 1 (TBK1) and increased downstream expression and activation of signal transducer and activator of transcription 1 (STAT1). Interrupting this autocrine feed forward loop by knocking out IFN-α/ß receptor completely restored infiltration of cytotoxic T cells and rescued loss of A20 depending tumorigenesis. Downstream of STAT1, programmed death ligand 1 (PD-L1) was highly expressed in A20 knockout lung tumors. Accordingly, immune checkpoint blockade (ICB) treatment was highly efficient in mice harboring A20-deficient lung tumors. Furthermore, an A20 loss-of-function gene expression signature positively correlated with survival of melanoma patients treated with anti-programmed cell death protein 1. Together, we have identified A20 as a master immune checkpoint regulating the TBK1-STAT1-PD-L1 axis that may be exploited to improve ICB therapy in patients with lung adenocarcinoma.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Necrosis Factor alpha-Induced Protein 3 / Adenocarcinoma of Lung / Lung Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Sci Transl Med Journal subject: CIENCIA / MEDICINA Year: 2021 Document type: Article Affiliation country: Austria

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Necrosis Factor alpha-Induced Protein 3 / Adenocarcinoma of Lung / Lung Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Sci Transl Med Journal subject: CIENCIA / MEDICINA Year: 2021 Document type: Article Affiliation country: Austria